FC
ADMA icon

Financial Consulate’s ADMA Biologics ADMA Stock Holding History

Financial Consulate’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27K Hold
3,000
– – ﹤0.01% 433
2025
Q4 		$54.7K Hold
3,000
– – 0.01% 303
2025
Q3 		$44K Buy
+3,000
New +$51.4K 0.01% 329

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Financial Consulate's ADMA Position: Q1 2026 in Review

Financial Consulate held its ADMA Biologics (ADMA) position steady in Q1 2026 at 3,000 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #433.

Financial Consulate first reported a position in ADMA in Q3 2025 and has held it in 3 quarters since. The position peaked at $54.7K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Financial Consulate held 3,000 shares of ADMA Biologics worth $27K as of Q1 2026.
  • Financial Consulate left its ADMA Biologics share count unchanged in Q1 2026.
  • ADMA Biologics made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #433 holding.
  • Financial Consulate first reported a position in ADMA Biologics in Q3 2025 and has held it in 3 quarters since.
  • Financial Consulate's ADMA Biologics position peaked at $54.7K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.